Head to Head Comparison: Genocea Biosciences (GNCA) versus The Competition
Genocea Biosciences (NASDAQ: GNCA) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Genocea Biosciences to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, dividends, valuation and analyst recommendations.
Institutional & Insider Ownership
34.8% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 47.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.7% of Genocea Biosciences shares are owned by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Genocea Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Genocea Biosciences Competitors||-3,290.23%||-530.46%||-39.66%|
Valuation & Earnings
This table compares Genocea Biosciences and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Genocea Biosciences||$230,000.00||-$49.57 million||-0.48|
|Genocea Biosciences Competitors||$217.29 million||-$39.39 million||-68.07|
Genocea Biosciences’ competitors have higher revenue and earnings than Genocea Biosciences. Genocea Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Genocea Biosciences has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, Genocea Biosciences’ competitors have a beta of 1.59, indicating that their average stock price is 59% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Genocea Biosciences and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Genocea Biosciences Competitors||542||2466||6677||126||2.65|
Genocea Biosciences presently has a consensus target price of $7.38, suggesting a potential upside of 609.13%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 16.06%. Given Genocea Biosciences’ higher probable upside, research analysts plainly believe Genocea Biosciences is more favorable than its competitors.
Genocea Biosciences competitors beat Genocea Biosciences on 8 of the 12 factors compared.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual’s tumor.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.